The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
V. M. Moyo
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
M. J. Higgins
Consultant or Advisory Role - Merrimack (U)
Research Funding - Merrimack
R. Aravelo-Araujo
Research Funding - Merrimack
N. Iannotti
Research Funding - Merrimack
V. Charu
Research Funding - Merrimack
N. Dhindsa
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
P. E. Goss
Consultant or Advisory Role - Merrimack
Research Funding - Merrimack